Abbott Norvir Compulsory Licensing Would Take Several Years, NIH Says
This article was originally published in The Pink Sheet Daily
Executive Summary
NIH cannot grant Norvir patent licenses under the Bayh/Dole Act until Abbott has exhausted its appeals process, and follow-on products would have to gain standard FDA approval, the agency says. NIH expects to make a decision on whether to apply its "march-in" authority for the HIV product as soon as possible. The precedent established could have an immediate effect; NIH received a petition requesting the use of march-in rights for Pfizer's Xalatan.
You may also be interested in...
GSK To Supply Combivir For NIH-Funded AIDS Trial Following Rep. Waxman Letter
GSK initially offered the HIV therapy for free but withdrew from the clinical trial in Africa after investigators revised one of three study arms, setting up a comparative effectiveness trial, Waxman says. GSK will now offer the drug at a "nonprofit," "developing country" price of 65¢ per day.
GSK To Supply Combivir For NIH-Funded AIDS Trial Following Rep. Waxman Letter
GSK initially offered the HIV therapy for free but withdrew from the clinical trial in Africa after investigators revised one of three study arms, setting up a comparative effectiveness trial, Waxman says. GSK will now offer the drug at a "nonprofit," "developing country" price of 65¢ per day.
Abbott Norvir Cost Chart Misrepresents Therapeutic Dose, Price – FDA Warning Letter
The pricing chart, created to explain a 2003 price increase, compares the cost of Norvir 100 mg daily to higher, labeled doses of other protease inhibitors, and implies that Norvir may be used as a monotherapy at a low dose, FDA said. The agency previously sent Abbott a letter citing Norvir promotional materials in 2001.